Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved

Dow Jones

3小时前

Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk.

The Danish company said Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity.

The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis.

Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones.

Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes.

Separately, the company said its board authorized a $400 million buyback.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2667699622"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667699622\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667699622?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 06:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667699622","market":"fut","top_or_hot":-1,"title":"Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk. \n</p>\n<p>\n  The Danish company said  Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. \n</p>\n<p>\n  The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis. \n</p>\n<p>\n  Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones. \n</p>\n<p>\n  Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes. \n</p>\n<p>\n  Separately, the company said its board authorized a $400 million buyback. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-15 06:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk. \n</p>\n<p>\n  The Danish company said  Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. \n</p>\n<p>\n  The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis. \n</p>\n<p>\n  Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones. \n</p>\n<p>\n  Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes. \n</p>\n<p>\n  Separately, the company said its board authorized a $400 million buyback. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2667699622","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667699622","pubTimestamp":1789425240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk.The Danish company said  Monday it can develop, manufacture","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MEDI":"HARBOR HEALTH CARE ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","ASND":"Ascendis Pharma A/S","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念"},"translate_title":"Ascendis Pharma 重新获得减肥技术权利；股份回购获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":0.9,"MEDI":0.6},"content_text":"Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk. \n\n\n  The Danish company said  Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. \n\n\n  The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis. \n\n\n  Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones. \n\n\n  Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes. \n\n\n  Separately, the company said its board authorized a $400 million buyback.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}